HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markham, C. H. Articles by Diamond, S. G. Search for Related Content PubMed PubMed Citation Articles by Markham, C. H. Articles by Diamond, S. G.

Evidence to support early levodopa therapy in Parkinson disease

From the Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA

To see whether duration of disease or of levodopa treatment was responsible for gradual worsening of parkinsonian patients, 58 persons treated with levodopa were classified into three groups based on predopa disease duration. Data over 6 years of treatment showed that disease duration was the determining factor. Patients matched for disease duration had similar disability scores regardless of duration of therapy. Matched for therapy duration, patients with longer disease duration had consistently higher disability scores. Side effects showed no differences between groups and did not increase over time. In sum, delaying therapy fails to improve disability in the early years of disease and does not confer any benefit in later years.

Address correspondence and reprint requests to Dr Markham, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA90024

Accepted for publication April 21, 1980

This article has been cited by other articles:

				F. Calon, M. Dridi, O. Hornykiewicz, P. J. Bedard, A. H. Rajput, and T. Di Paolo Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias Brain, May 1, 2004; 127(5): 1075 - 1084. [Abstract] [Full Text] [PDF]

				C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]

				W. J. Weiner Is Levodopa Toxic? Arch Neurol, March 1, 2000; 57(3): 408 - 410. [Full Text] [PDF]

				W. C. Koller, J. T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study Neurology, September 1, 1999; 53(5): 1012 - 1012. [Abstract] [Full Text] [PDF]

				S. Fahn Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial Arch Neurol, May 1, 1999; 56(5): 529 - 535. [Full Text] [PDF]

				G. W. Paulson Therapy of Patients With Parkinson's Disease Arch Neurol, August 1, 1994; 51(8): 754 - 756. [Abstract] [PDF]

				S. G. Diamond, C. H. Markham, R. W. Rand, D. P. Becker, and L. J. Treciokas Four-Year Follow-up of Adrenal-to-Brain Transplants in Parkinson's Disease Arch Neurol, June 1, 1994; 51(6): 559 - 563. [Abstract] [PDF]

				E. Melamed Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed Until the Advanced Stages of the Disease Arch Neurol, April 1, 1986; 43(4): 402 - 405. [Abstract] [PDF]

				C. H. Markham and S. G. Diamond Modification of Parkinson's Disease by Long-term Levodopa Treatment Arch Neurol, April 1, 1986; 43(4): 405 - 407. [Abstract] [PDF]

				W. C. Koller Pharmacologic Treatment of Parkinsonian Tremor Arch Neurol, February 1, 1986; 43(2): 126 - 127. [Abstract] [PDF]

				N. Geschwind and A. M. Galaburda Cerebral Lateralization: Biological Mechanisms, Associations, and Pathology: III. A Hypothesis and a Program for Research Arch Neurol, July 1, 1985; 42(7): 634 - 654. [Abstract] [PDF]

				W. W. Tourtellotte, K. Syndulko, and A. R. Potvin Carbidopa-Levodopa Ratio in Parkinson's Disease Arch Neurol, November 1, 1981; 38(11): 737 - 738. [Abstract] [PDF]